neutralizingantibodiesagainststructurallydistinctdomainsofH3N2HA. Vaccines
64. Portnoff,A.D.etal.Influenzahemagglutininnanoparticlevaccineelicitsbroadly
hemagglutininfusionmachineryoninfluenzavirions. Sci.Adv. 6,eaaz8822(2020).
63. Benhaim, M. A. etal. Structural monitoring of a transient intermediate in the
allinfluenzaAsubtypes. Cell 166,596–608(2016).
62. Kallewaard,N.L.etal.Structureandfunctionanalysisofanantibodyrecognizing
epitope. Science 324,246–251(2009).
61. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus
differentinfluenzavaccineplatformsinhumans. Nat.Commun. 10,3338(2019).
60. Khurana,S.etal.Repeatvaccinationreducesantibodyaffinitymaturationacross
e3000139(2019).
separation of hemagglutinin receptor-binding head domains. PLoS Biol. 17,
59. Turner,H.L.etal.Potentanti-influenzaH7humanmonoclonalantibodyinduces
(2015).
broadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 386, 323–341
58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationofviralepitopesrecognizedby
(1983).
hemagglutininmoleculeofH3influenzavirusatacidicpH. Virology 126,587–599
57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Changesintheantigenicityofthe
insectandmammaliancells. Curr.Opin.Biotechnol. 10,428–433(1999).
56. Kost,T.A.&Condreay,J.P.Recombinantbaculovirusesasexpressionvectorsfor
revealsstructuralpolymorphisms. Clin.Vaccin.Immunol. 23,483–495(2016).
hemagglutinin complexes by cryo-electron microscopy and image analyses
55. McCraw,D.M.,Gallagher,J.R.&Harris,A.K.Characterizationofinfluenzavaccine
perspective. AnnuRev.Biophys. 47,153–173(2018).
54. Boonstra, S. et al. Hemagglutinin-mediated membrane fusion: a biophysical
406–430(2015).
enza: the role of the haemagglutinin cleavage site motif. Rev. Med Virol. 25,
53. Luczo,J.M.etal.MolecularpathogenesisofH5highlypathogenicavianinflu-
95,409–417(1998).
minantofinfluenzapathogenicityandtheoriginofthelabileconformation. Cell
52. Chen,J.etal.Structureofthehemagglutininprecursorcleavagesite,adeter-
(1992).PMC556715.
siteisactivatedbyfurin,asubtilisin-likeendoprotease. EMBOJ. 11,2407–2414
51. Stieneke-Gröber,A.etal.Influenzavirushemagglutininwithmultibasiccleavage
laughingmatter. Proc.NatlAcad.Sci.USA 95,9713–9715(1998).
50. Taubenberger, J.K.Influenzavirus hemagglutinin cleavageintoHA1,HA2:no
sed19April2021.
drug-products/applications-submissions/register-innovative-drugs.html. Acces-
from https://www.canada.ca/en/health-canada/services/drugs-health-products/
49. HealthCanada.RegisterofInnovativeDrugs[Updated15April2021].Available
February2021.
assessment-report/supemtek-epar-public-assessment-report_en.pdf. Accessed 17
EMEA/H/C/005159/0000. Available at https://www.ema.europa.eu/en/documents/
48. European Medicines Agency. Assessment report. Supemtek. Procedure No.
2021.
azureedge.net/media/documents/VAC_infl_publ_rpt_10-07.pdf. Accessed August
47. Influenza vaccine strategies for broad global access. Available at https://path.
particles. ExpertRev.Vaccines 12,225–236(2013).
46. Fernandes,F.etal.Insectcellsasaproductionplatformofcomplexvirus-like
ticlevaccine. Biopharm.Int 23Suppl10,26–34(2010).